MRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with High molecular weight melanoma-associated antigen-specific monoclonal antibody beads

Clinical Chemistry

Volumn 55, Issue 4, 2009, Pages 757-764

  Kitago, Minoru ^a   Koyanagi, Kazuo ^a   Nakamura, Takeshi ^a   Goto, Yasufumi ^a   Faries, Mark ^a   O'day, Steven J ^b   Morton, Donald L ^a   Ferrone, Soldano ^c   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b Research Institute   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BIOLOGICAL MARKER; DNA; MELANOMA ANTIGEN; MESSENGER RNA; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MONOCLONAL ANTIBODY; MUTANT PROTEIN; PEPTIDE NUCLEIC ACID; TRANSCRIPTOME; BRAF PROTEIN, HUMAN; HMW MAA; HMW-MAA; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; BLOOD; BLOOD CELL; BLOOD SAMPLING; CELL ISOLATION; CONTROLLED STUDY; DNA EXTRACTION; DONOR; GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOMICS; HUMAN; HUMAN CELL; MAGEA3 GENE; MAJOR CLINICAL STUDY; MALE; MELANOMA CELL; MITF GENE; MLANA GENE; MOLECULAR WEIGHT; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CELL SEPARATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LEUKOCYTE; MELANOMA; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE; TUMOR EMBOLISM;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELL SEPARATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTES; MELANOMA; MUTATION; NEOPLASTIC CELLS, CIRCULATING; PROTO-ONCOGENE PROTEINS B-RAF; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 64149093514     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.116467     Document Type: Article

References (28)

1. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cas- cinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging sys- tem for cutaneous melanoma. J Clin Oncol 2001; 19:3635-48.
2. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M, eds. AJCC cancer staging manual. 6th ed. New York: Springer- Verlag; 2002. 421 p.
3. Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, Lorico AR Jr, et al. Multimarker quantitative real- time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 2005;51:981-8.
4. Mellado B, Gutierrez L, Castel T, Colomer D, Fontanillas M, Castro J, Estape J. Prognostic sig- nificance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free mel- anoma patients. Clin Cancer Res 1999;5:1843-8.
5. Palmieri G, Strazzullo M, Ascierto PA, Satriano SM, Daponte A, Castello G. Polymerase chain reaction-based detection of circulating melanoma cells as an effective marker of tumor progression. Melanoma Cooperative Group. J Clin Oncol 1999; 17:304-11.
6. Pantel K, Cote RJ, Fodstad O. Detection and clinical importance of micrometastatic disease. J Natl Cancer Inst 1999;91:1113-24.
7. Taback B, Morton DL, O'Day SJ, Nguyen DH, Nakayama T, Hoon DS. The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma. Recent Results Cancer Res 2001;158:78-92.
8. Wascher RA, Morton DL, Kuo C, Elashoff RM, Wang HJ, Gerami M, Hoon DS. Molecular tumor markers in the blood: early prediction of dis- ease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol 2003; 21:2558-63.
9. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Robin- son WA, Amatruda TT, et al. Microphthalmia tran- scription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res 2006;12:1137-43.
10. Koyanagi K, O'Day SJ, Gonzalez R, Lewis K, Rob- inson WA, Amatruda TT, et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: out- come prediction in a multicenter trial. J Clin Oncol 2005;23:8057-64.
11. Takeuchi H, Kuo C, Morton DL, Wang HJ, Hoon DS. Expression of differentiation melanoma- associated antigen genes is associated with fa- vorable disease outcome in advanced-stage mel- anomas. Cancer Res 2003;63:441-8.
12. Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, Elashoff R, et al. Prognostic signifi- cance of molecular upstaging of paraffin- embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 2004;22:2671-80.
13. Miyashiro I, Kuo C, Huynh K, Iida A, Morton D, Bilchik A, et al. Molecular strategy for detecting metastatic cancers with use of multiple tumor- specific MAGE-A genes. Clin Chem 2001;47:505-12.
14. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrat- ing into tumor. Proc Natl Acad Sci U S A 1994; 91:3515-9.
15. Davis IJ, Kim JJ, Ozsolak F, Widlund HR, Rozenblatt-Rosen O, Granter SR, et al. Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. Cancer Cell 2006;9:473-84.
16. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clini- cal relevance for primary cutaneous melanomas. Clin Cancer Res 2004;10:1753-7.
17. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
18. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu- Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67.
19. Shinozaki M, O'Day SJ, Kitago M, Amersi F, Kuo C, Kim J, et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma pa- tients receiving biochemotherapy. Clin Cancer Res 2007;13:2068-74.
20. Takeuchi H, Fujimoto A, Tanaka M, Yamano T, Hsueh E, Hoon DS. CCL21 chemokine regulates chemokine receptor CCR7 bearing malignant mela- noma cells. Clin Cancer Res 2004;10:2351-8.
21. Goto Y, Ferrone S, Arigami T, Kitago M, Tane- mura A, Sunami E, et al. Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res 2008;14:3401-8.
22. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW- MAA): a melanoma cell surface chondroitin sul- fate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol 2004;24: 267-96.
23. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S. Purification of murine IgG mono- clonal antibodies by precipitation with caprylic acid: comparison with other methods of purifica- tion. Hybridoma 1989;8:85-95.
24. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DS. Epigenetic inactivation of RAS as- sociation domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res 2003;63:1639-43.
25. Kim J, Giuliano AE, Turner RR, Gaffney RE, Umet- ani N, Kitago M, et al. Lymphatic mapping estab- lishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 2006;244:799-804.
26. Hoon DS, Wang Y, Dale PS, Conrad AJ, Schmid P, Garrison D, et al. Detection of occult mela- noma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol 1995;13:2109-16.
27. Michaloglou C, Vredeveld LC, Soengas MS, De- noyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4.
28. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mu- tations in EGFR in circulating lung-cancer cells. N Engl J Med 2008;359:366-77.